Ongoing Clinical Trials for Vertigo
Currently, there is one ongoing clinical trial investigating treatments for vertigo. This trial is being conducted in the Netherlands and focuses on Menière’s disease, a disorder of the inner ear that causes vertigo episodes. The study is examining whether intratympanic injections of methylprednisolone, a corticosteroid medication, can effectively reduce the frequency of vertigo attacks compared to a placebo.
Clinical trial locations
Study on Meniere’s Disease: Comparing Methylprednisolone and Placebo for Patients with Unilateral Meniere’s Disease
This trial is investigating whether methylprednisolone injections can help reduce vertigo attacks in people with Menière’s disease, a condition affecting the inner ear that causes episodes of spinning sensations, hearing problems, ringing in the ears, and feelings of pressure or fullness in the ear.
Who can participate:
- Adults over 18 years old
- People diagnosed with unilateral Menière’s disease, meaning the condition affects only one ear
- Those who have experienced at least 4 vertigo attacks in the past 6 months
- Both men and women are eligible
Who cannot participate:
- People without a confirmed diagnosis of unilateral Menière’s disease
- Those outside the specified age range
- Vulnerable populations such as children, pregnant women, or individuals unable to provide informed consent
- People with other medical conditions that could interfere with the study
- Those currently enrolled in another clinical trial
- People with allergies or adverse reactions to the study medication
- Those who have recently undergone surgery or medical procedures that might affect the study
- People unable to follow study procedures or attend follow-up visits
What the trial involves:
The study uses a treatment method called intratympanic injection, where medication is injected directly into the ear. Participants will receive either methylprednisolone at a dose of 62.5 mg/ml or a placebo over the course of one year. The goal is to determine whether the medication is more effective than placebo in reducing the frequency of vertigo attacks.
Investigational medication:
Methylprednisolone is a corticosteroid medication that works by reducing inflammation and suppressing the immune response. By injecting it directly into the ear, the medication can target the affected area more effectively. This approach is designed to reduce the inflammation in the inner ear that contributes to vertigo episodes.
Monitoring and follow-up:
Throughout the trial, participants will undergo regular check-ups and assessments to monitor their response to treatment. This includes tracking the frequency of vertigo attacks, hearing changes, and overall quality of life. Participants may be asked to complete questionnaires about their symptoms, including dizziness and tinnitus. The study will also evaluate the use of other medications such as metoclopramide to manage nausea and vomiting that commonly occur during vertigo attacks.
Summary
There is currently one active clinical trial addressing vertigo, specifically in patients with Menière’s disease. This trial is taking place in the Netherlands and focuses on evaluating whether intratympanic methylprednisolone injections can effectively reduce vertigo attacks compared to placebo treatment. The study represents an important investigation into corticosteroid therapy for managing this challenging condition, which significantly impacts patients’ quality of life due to unpredictable episodes of vertigo, hearing loss, and associated symptoms. The trial is designed to provide evidence about the safety and effectiveness of this targeted treatment approach over a one-year period.
